NEW YORK, NY--(Marketwire - April 13, 2010) -
Aoxing Pharmaceutical Company, Inc. (OTCBB: CAXGD
) ("Aoxing Pharma"), a specialty pharmaceutical company focusing on research, development, manufacturing and distribution of narcotic and pain-management products, today announced that it received authorization to list its common stock on the NYSE AMEX market.
Aoxing Pharma expects to begin trading on NYSE AMEX, a subsidiary of NYSE Euronext, on Wednesday, April 14, 2010 under the ticker "AXN," until which time its common stock will continue to trade on the Over the Counter Bulletin Board under the symbol "CAXGD."
"We are excited to report that our application to list on NYSE AMEX has been approved," said Mr. Zhenjiang Yue, chairman and CEO of Aoxing Pharma. "This is a very important milestone for our company and shareholders. Being listed on NYSE AMEX provides us with greater visibility for our company, more liquidity for our stock and the opportunity to further expand our investor base. Furthermore, it enhances our corporate image to our industrial peers as our drug industry is international by nature and we continue striking on global business collaboration and market expansion. I believe that this move will deliver increased value for our shareholders now and down the road."
About Aoxing Pharmaceutical Company, Inc.
Aoxing Pharmaceutical Company, Inc. is a US incorporated specialty pharmaceutical company with its main operations in China, specializing in research, development, manufacturing and distribution of a variety of narcotics and pain-management products. Headquartered in Shijiazhuang City, outside Beijing, Aoxing has the largest and most advanced manufacturing facility for highly regulated narcotic medicines. Its facility is one of the few GMP facilities licensed for the manufacture of narcotic medicines by the China State Food and Drug Administration (SFDA). It has strategic alliances with QRxPharma and American Oriental Bioengineering, Inc. For more information: www.chinapainmed.com.
Safe Harbor Statement from Aoxing Pharmaceutical Company, Inc.
Statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements. The economic, competitive, governmental, technological and other risk factors identified in the Company's filings with the Securities and Exchange Commission, including the Form 10-K for the year ended June 30, 2009, may cause actual results or events to differ materially from those described in the forward looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.